■局部治疗旨在为前列腺癌(PCa)男性提供持久的肿瘤治疗选择,同时保持他们的生活质量。大多数局灶性治疗方式依赖于直接的组织效应,导致可能的非靶向消融方法。这里,我们报告了首次使用纳米粒子导向聚焦光热消融治疗PCa的人体可行性试验的结果.
■预期的开放标签,我们对Gleason分级组(GGG)1~3中患有局限性PCa的男性进行了单臂多中心研究.男性接受了一次金纳米颗粒(AuroShells)的输注,随后MR/US融合引导激光激发靶组织以诱导光热消融。MRI用于评估48至96小时前列腺组织消融的有效性,3个月,治疗后12个月。3个月时,对病灶进行靶向性融合活检.在12个月时,进行靶向融合活检和标准模板活检。基于治疗区域内的阴性MR/US融合活检结果来确定治疗成功。
■46名男性参加了这项研究,44名45个病变的男性完成了纳米粒子输注和激光治疗。基线时的平均PSA水平为9.5ng/mL,3个月时下降5.9ng/mL,12个月时下降4.7ng/mL(P<0.0001)。3个月和12个月的肿瘤成功率导致44例患者中的29例(66%)和32例(73%),分别,在消融区MR/US融合活检阴性证实成功治疗。在GGG中,MRI最大病灶直径(MLD),前列腺体积,和PI-RADS评分,MLD与12个月时治疗失败的几率显著相关(P=0.046).
■肿瘤前列腺组织的纳米粒子定向聚焦激光消融导致73%的患者在治疗后12个月成功治疗,经治疗病变的MR/US融合活检阴性和系统活检证实。
UNASSIGNED: Focal therapy aims to provide a durable oncologic treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for PCa.
UNASSIGNED: A prospective, open-label, single-arm, multicenter study of men with localized PCa in Gleason Grade Group 1 to 3 was conducted. Men received a single infusion of gold nanoparticles (AuroShells), followed by magnetic resonance (MR)/ultrasound (US) fusion-guided laser excitation of the target tissue to induce photothermal ablation. MRI was used to assess the effectiveness of prostate tissue ablation at 48 to 96 hours, 3 months, and 12 months post treatment. At 3 months, a targeted fusion biopsy of the lesion(s) was conducted. At 12 months, a targeted fusion biopsy and standard templated biopsy were performed. Treatment success was determined based on a negative MR/US fusion biopsy outcome within the treated area.
UNASSIGNED: Forty-six men were enrolled in the study, and 44 men with 45 lesions completed nanoparticle infusion and laser treatment. The mean PSA level at baseline was 9.5 ng/mL, which decreased to 5.9 ng/mL at 3 months and to 4.7 ng/mL at 12 months (P < .0001). The oncologic success rates at 3 and 12 months resulted in 29 (66%) and 32 (73%) of 44 patients, respectively, being successfully treated, confirmed with negative MR/US fusion biopsies within the ablation zone. Among Gleason Grade Group, maximum lesion diameter on MRI, prostate volume, and Prostate Imaging Reporting and Data System scoring, the maximum lesion diameter was significantly associated with the odds of treatment failure at 12 months (P = .046).
UNASSIGNED: Nanoparticle-directed focal laser ablation of neoplastic prostate tissue resulted in 73% of patients with successful treatment at 12 months post treatment, confirmed by negative MR/US fusion biopsy of the treated lesion and a systematic biopsy.
UNASSIGNED: 02680535.